World Organisation for Animal Health

FOOT AND MOUTH VACCINE PRODUCTION & SUPPLY IN KENYA

EXPERIENCES AND LESSONS LEARNT

Alex Zephania Sabuni
Managing Director, KEVEVAPI

Workshop on FMD Epidemiology, Surveillance, and Diagnostics to Strengthen Control Efforts in Eastern Africa
21st - 23rd October 2025, Mombasa, Kenya

COMESA SPS Project

History of FMD in Kenya

- Foot-and-mouth disease (FMD) was first detected in Kenya in 1915 and was serotyped in 1932.
- Following independence in 1964, Kenya implemented a comprehensive FMD control program that initially showed success but was ultimately discontinued- political, funding.
- Until recent, FMD remained endemic in Kenya, with control efforts focusing on outbreak management and a mix of public and private vaccination efforts.
- Currently, National Livestock vaccination programme against FMD and PPR disease

FMD vaccine manufacturing in Kenya

- 1957: The Wellcome Institute for Research on Foot and Mouth Disease (WIRFMD) was established in Embakasi as a joint venture between the Wellcome Trust Foundation and the Kenyan government.
- 1964: The FMD vaccine production process began at the institute's precursor, the Vaccine Production Laboratory at Embakasi.
- 1990: The Kenya Veterinary Vaccines Production Institute (KEVEVAPI) was established as a state corporation, formalizing the country's vaccine production capabilities.

Status of FMD vaccine manufacturing in Kenya



World Organisation for Animal Health

National Livestock Vaccination program

Targets to vaccinate 22M cattle against FMD, and 50M sheep and goats against PPR diseases

To run for at least 3 years

Vaccine supply from KEVEVAPI and other supplies

National livestock vaccination campaign

KEVEVAPI plays a critical role in the production and supply of Foot-and-Mouth Disease & other vaccines used for the exc.

e-Voucher initiative - technological progress

(vaccine procurement, distribution, coverage, and traceability via digital platforms.

1. Safeguarding livestock health
2. Promoting trade
3. Enhancing economic resilience

PREPAREDNESS OF KEVEVAPI TO MEET DEMAND

The modernization started in 2011, supported by National Treasury, GALVMED and the European Union to expand vaccine production.

Added a bio-reactor and optimized the production system to boost antigen output.

Secured World Bank funding to purchase key equipment, including bio-reactors, filling, vial processing, and freeze-drying units.

Partnered with Safaricom to create a real-time system for tracking raw materials and vaccines to maintain smooth production and distribution.

Fostering trust in veterinary vaccine manufacturing and supply

Share updates on vaccine development, quality, and supply with stakeholders via regular reports and meeting, ensuring ethical standards.

Stakeholder engagement: involve farmers, veterinarians, regulators, and distributors in decisions and feedback.

Quality assurance: maintain strict quality checks and share certifications and audit results publicly.

Customer support: offer accessible channels for prompt responses to stakeholder queries and concerns.

Partnerships: partner with organizations, researchers, and agencies to boost credibility and best practices.

Supply chain management: maintain consistent vaccine availability and provide transparent updates regarding changes.

CHALLENGES IN MEETING DEMAND

- Budget limitations
- Timely availability and procurement of raw materials
- Inconsistent vaccine orders and therefore inadequate planning
- Ageing infrastructure

ACTIONS TO MANAGE CHALLENGES

- ❑ Lobbying for **resources (WB, DTRA)**
- ❑ Consistently **onboarding of new raw material suppliers**
- ❑ With national vaccination *planning huddle is overcome*
- ❑ **Secured funding** though inconsistent for modernization
- ❑ Objective engagement with partners

FUTURE PLANS

Short to Mid-term

- ❑ Modernize and expand capacity to manufacture vaccine for the National program
- ❑ Establish regional cold-chain facilities for ease of vaccine distribution

Long-term

- ❑ Construct a state of art Vaccine production facility for FMD and other vaccines